Literature DB >> 27195965

Multi-Dimensional Impact of the Public-Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21(st) Century Institutional Designs to Support Innovation-in-Society.

Lotte M Steuten1,2.   

Abstract

Knowledge translation is at the epicenter of 21st century life sciences and integrative biology. Several innovative institutional designs have been formulated to cultivate knowledge translation. One of these organizational innovations has been the Center for Translational Molecular Medicine (CTMM), a multi-million public-private partnership in the Netherlands. The CTMM aims to accelerate molecular diagnostics and imaging technologies to forecast disease susceptibilities in healthy populations and early diagnosis and personalized treatment of patients. This research evaluated CTMM's impact on scientific, translational, clinical, and economic dimensions. A pragmatic, operationally-defined process indicators approach was used. Data were gathered from CTMM administrations, through a CTMM-wide survey (n = 167) and group interviews. We found that the CTMM focused on disease areas with high human, clinical, and economic burden to society (i.e., oncology, cardiovascular, neurologic, infection, and immunity diseases). CTMM displayed a robust scientific impact that rests 15%-80% above international reference values regarding publication volume and impact. Technology translation to the clinic was accelerated, with >50% of projects progressing from pre-clinical development to clinical testing within 5 years. Furthermore, CTMM has generated nearly 1500 Full Time Equivalent (FTE) of translational R&D capacity. Its positive impact on translational, (future) clinical, and economic aspects is recognized across all surveyed stakeholders. As organizational innovation is increasingly considered critical to forge linkages between life sciences discoveries and innovation-in-society, lessons learned from this study may inform other institutions with similar objectives such as the Clinical and Translational Science Awards (CTSA) Program of the National Institutes of Health (NIH) in the United States.

Entities:  

Mesh:

Year:  2016        PMID: 27195965      PMCID: PMC4876525          DOI: 10.1089/omi.2016.0042

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  15 in total

Review 1.  How can payback from health services research be assessed?

Authors:  M Buxton; S Hanney
Journal:  J Health Serv Res Policy       Date:  1996-01

2.  Practice-based research--"Blue Highways" on the NIH roadmap.

Authors:  John M Westfall; James Mold; Lyle Fagnan
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

3.  Asia's ascent--global trends in biomedical R&D expenditures.

Authors:  Justin Chakma; Gordon H Sun; Jeffrey D Steinberg; Stephen M Sammut; Reshma Jagsi
Journal:  N Engl J Med       Date:  2014-01-02       Impact factor: 91.245

4.  Evaluating translational research: a process marker model.

Authors:  William Trochim; Cathleen Kane; Mark J Graham; Harold A Pincus
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

5.  Early assessment of medical technologies to inform product development and market access: a review of methods and applications.

Authors:  Maarten J Ijzerman; Lotte M G Steuten
Journal:  Appl Health Econ Health Policy       Date:  2011-09-01       Impact factor: 2.561

6.  A method for the early health technology assessment of novel biomarker measurement in primary prevention programs.

Authors:  Douwe Postmus; Gimon de Graaf; Hans L Hillege; Ewout W Steyerberg; Erik Buskens
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

7.  Tracing the wider impacts of biomedical research: a literature search to develop a novel citation categorisation technique.

Authors:  Teresa H Jones; Claire Donovan; Steve Hanney
Journal:  Scientometrics       Date:  2012-02-01       Impact factor: 3.238

8.  Describing the impact of health research: a Research Impact Framework.

Authors:  Shyama Kuruvilla; Nicholas Mays; Andrew Pleasant; Gill Walt
Journal:  BMC Health Serv Res       Date:  2006-10-18       Impact factor: 2.655

9.  Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study.

Authors:  Ron L H Handels; Pauline Aalten; Claire A G Wolfs; Marcel OldeRikkert; Philip Scheltens; Pieter Jelle Visser; Manuela A Joore; Johan L Severens; Frans R J Verhey
Journal:  BMC Neurol       Date:  2012-08-10       Impact factor: 2.474

10.  Expanding assessments of translational research programs: supplementing metrics with value judgments.

Authors:  Craig S Scott; Pamela R Nagasawa; Neil F Abernethy; Bonnie W Ramsey; Paul J Martin; Beth M Hacker; Havivah D Schwartz; Douglas M Brock; Lynn S Robins; Fred M Wolf; Marie Carter-Dubois; Mary L Disis
Journal:  Eval Health Prof       Date:  2013-09-23       Impact factor: 2.651

View more
  1 in total

1.  Nursing Observation on the Clinical Efficacy and Toxicity of Lobaplatin Compared with Cisplatin in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Based on Intelligent CT Imaging.

Authors:  Yunyan Li; Guangrun Yang; Mengmeng Li; Xu Tong
Journal:  J Healthc Eng       Date:  2021-06-30       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.